- Home
- BTBT vs PHVS Comparison
BTBT vs PHVS Comparison
Compare BTBT & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BTBT
- PHVS
- Stock Information
- Founded
- BTBT 2015
- PHVS 2015
- Country
- BTBT United States
- PHVS Switzerland
- Employees
- BTBT N/A
- PHVS N/A
- Industry
- BTBT Finance: Consumer Services
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- BTBT Finance
- PHVS Health Care
- Exchange
- BTBT Nasdaq
- PHVS Nasdaq
- Market Cap
- BTBT 1.1B
- PHVS 980.9M
- IPO Year
- BTBT 2018
- PHVS 2021
- Fundamental
- Price
- BTBT $2.99
- PHVS $20.12
- Analyst Decision
- BTBT Strong Buy
- PHVS Buy
- Analyst Count
- BTBT 3
- PHVS 6
- Target Price
- BTBT $6.33
- PHVS $37.17
- AVG Volume (30 Days)
- BTBT 46.6M
- PHVS 215.4K
- Earning Date
- BTBT 08-18-2025
- PHVS 08-13-2025
- Dividend Yield
- BTBT N/A
- PHVS N/A
- EPS Growth
- BTBT N/A
- PHVS N/A
- EPS
- BTBT N/A
- PHVS N/A
- Revenue
- BTBT $102,037,923.00
- PHVS N/A
- Revenue This Year
- BTBT $20.87
- PHVS N/A
- Revenue Next Year
- BTBT $38.28
- PHVS N/A
- P/E Ratio
- BTBT N/A
- PHVS N/A
- Revenue Growth
- BTBT 52.44
- PHVS N/A
- 52 Week Low
- BTBT $1.69
- PHVS $11.51
- 52 Week High
- BTBT $5.74
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- BTBT 48.44
- PHVS 48.68
- Support Level
- BTBT $2.66
- PHVS $19.12
- Resistance Level
- BTBT $3.64
- PHVS $22.30
- Average True Range (ATR)
- BTBT 0.28
- PHVS 1.22
- MACD
- BTBT -0.04
- PHVS -0.23
- Stochastic Oscillator
- BTBT 33.67
- PHVS 22.17
About BTBT Bit Digital Inc.
Bit Digital Inc is engaged in the Bitcoin mining business, Ethereum staking activities and specialized cloud-infrastructure services for artificial intelligence applications through its wholly owned subsidiaries. Its mining platform operates with the primary intent of accumulating bitcoin which may sell for fiat currency from time to time depending on market conditions. The Company has four reportable segments: digital asset mining, cloud services, colocation services, and ETH Staking. It generates majority of its revenue from digital asset mining.
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.